London-Based Cælum Capital Limited Invests in Pioneering Scotch Whisky Business – Compass Box
Cælum Capital Limited, a specialist investor focused on premium beverage businesses, announced the acquisition of a majority stake in Compass Box Delicious Whisky Limited, a London-based premium Scotch whisky brand. Compass Box is ranked 4th in the “Top Trending Brands” in Scotch whisky segment by Drinks International.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005290/en/
London-Based Cælum Capital Limited Invests in Pioneering Scotch Whisky Business – Compass Box (Photo: Business Wire)
Cælum was set up by Manish Rungta, an ex-Diageo executive with a background in private equity. Cælum has brought in Maurice Doyle as the new CEO of Compass Box to partner with the Founder, John Glaser, in the continued development of the business. A spirits industry veteran, Maurice Doyle brings nearly 30 years of marketing, commercial, and executive leadership experience from within the global alcoholic beverages sector. “I am delighted to be joining Compass Box. It is a brand that I have long admired as a pioneer within Scotch whisky. I have a huge amount of respect for John and what he has achieved,” says Doyle.
Founded in London in 2000, Compass Box is a reflection of Glaser’s personal vision for what the future of whisky making should be. John Glaser was named by Whisky Advocate as one of the “Thirty Innovators Who Shaped Today’s Whisky” and one of the only Two alive today. “With Maurice joining me at the helm, we are excited to double-down on our determination to democratise the enjoyment of Scotch whisky, to continue releasing products that reveal the creative art behind blending,” says Glaser, who has described the Compass Box mission as, “fighting…what I call the ‘single malt hegemony.’”
Cælum investment will be used to strengthen the balance sheet of the Company, acquire inventory, and build production facilities. Cælum will help facilitate the ambition of Compass Box to provide more opportunities to explore, experiment and innovate, with curiosity and creativity as its guiding principles. Manish Rungta, the Managing Partner at Cælum said, “We are excited to partner with Compass Box and it is representative of the innovative and pioneering brands within the beverage category that we would like to invest behind.”
Metric Point Capital, acted as the exclusive financial advisor and placement agent to Cælum. “We are thankful for the support of the Metric Point team during a very complex process and a crowded North American fundraising market. Metric Point brought highly technical skillsets and a tailored solution for this unique proprietary deal and we ended up being oversubscribed in our fundraising,” said Manish Rungta.
Corporate Partner Tom Braiden led the team at Brown Rudnick, an international law firm, which acted as exclusive legal advisor to Cælum.
Cælum Capital Limited
Cælum Capital Limited is based in London and is a specialist investor focused on investing in premium beverage businesses based in North America and Europe with a focus on alcoholic beverages. Cælum was founded by Manish Rungta, who is the Managing Partner of the firm and has extensive investment experience in the beverage sector, both alcoholic and non-alcoholic. Ex-SABMiller executive Mark Eames has joined Cælum as an Operating Partner and has extensive strategic, operational, and financial planning experience within the beverage sector. Cælum targets opportunities in the beverage segment with investment amounts ranging from US$50 – 200 million. For more information, please visit www.caelumcap.co.uk.
Compass Box are Scotch whiskymakers. The word ‘whiskymaker’ is their word – it does not appear in a dictionary. For over 20 years they have been relentlessly focused on reinventing Scotch whisky, with every new blend designed to help make the world of whisky a more interesting place. Compass Box have won more awards for innovation than any other producer in Scotland because they are always experimenting. Always looking for sparks of creativity that will deliver something totally compelling, yet completely surprising. This vision motivates them as whiskymakers. Their blends are consistently rated equal to or better than the great single malts of Scotland by the most respected voices in the industry. For more information, please visit www.compassboxwhisky.com or @CompassBoxWhiskyCo on Instagram.
Metric Point Capital(Member FINRA and SIPC)
Metric Point Capital is a boutique private capital advisory firm specializing in raising institutional capital for alternative investment managers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting27.5.2022 15:00:00 CEST | Press release
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number：e16102 Abstract Title：Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses . Approximately 50% of the advanced GC patients will develop p
FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 202227.5.2022 13:38:00 CEST | Press release
FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/ (Photo: Business Wire) As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disp
Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture27.5.2022 09:00:00 CEST | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have won the SCF Small Cell Awards 2022 for Outstanding Contribution to Emerging Technology or Architecture, for its design and delivery of the first fully containerized small cell Open Virtualized Radio Access Network (Open vRAN), for indoor and outdoor connectivity. Mavenir’s containerized Open vRAN solution is a first of its kind and combines the interoperability of Open RAN with the portability and flexibility of containers. This small cell solution brings the same future-forward approaches of Open RAN and containerization having significant impacts in macro networks to small cell networks. The deployment of a containerized solution is a significant milestone in the evolution of connectivity, moving away from the physical infrastructure to a digital cloud-based environment. Containers take virtualizati
TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 202227.5.2022 09:00:00 CEST | Press release
TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/ TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire) “The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s ser
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination